comparemela.com

Latest Breaking News On - Leisure acquisition - Page 5 : comparemela.com

SHAREHOLDER ALERT: WeissLaw LLP Reminds LACQ, GWPH, PRSP, and CMD Shareholders About Its Ongoing Investigations

Leisure Acquisition Corp. (NASDAQ: LACQ) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Leisure Acquisition Corp. (NASDAQ: LACQ), in connection with the company s proposed merger with Ensysce Biosciences, Inc. ( Ensysce ).  Under the terms of the merger agreement, LACQ will acquire Ensysce through a reverse merger that will result in Ensysce becoming a public company traded on the NASDAQ.  If you own LACQ shares and wish to discuss this investigation or your rights, please call or visit our website: http://www.weisslawllp.com/lacq/   GW Pharmaceuticals plc (NASDAQ: GWPH)

Ensysce Biosciences, Inc And Leisure Acquisition Corp Announce Appointment Of Dave Humphrey As Chief Financial Officer

Share this article Share this article NEW YORK and SAN DIEGO, Feb. 18, 2021 /PRNewswire/ Ensysce Biosciences Inc. ( Ensysce ), a clinical stage pharmaceutical company developing medicines for severe pain relief to reduce fear of addiction, opioid misuse, abuse and overdose, and Leisure Acquisition Corp. (NASDAQ: LACQ) ( LACQ ) today announced the appointment of David Humphrey to Ensysce s management team as its Chief Financial Officer. Mr. Humphrey brings over 20 years of experience with development-stage companies as they progress toward product commercialization. Prior to joining Ensysce, Mr. Humphrey was Chief Financial Officer of Senomyx, Inc., a publicly-held biotechnology company which he led through an acquisition by Firmenich SA, a private Swiss multinational flavor and fragrance company.  As part of his responsibilities, he will oversee financial strategy and business expansion at Ensysce, in addition to assisting with Ensysce s proposed business combination with LA

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.